細胞・遺伝子治療製造サービス市場：タイプ、適応症、用途、エンドユーザー別-2025-2030年世界予測

細胞・遺伝子治療製造サービス市場は、2023年に173億4,000万米ドルと評価され、2024年には199億8,000万米ドルに達すると予測され、CAGR 15.81％で成長し、2030年には484億5,000万米ドルに達すると予測されています。

細胞・遺伝子治療製造サービスには、細胞ベースおよび遺伝子改変療法の製造に関わる幅広いプロセスが含まれます。これらのサービスには、細胞培養、ウイルスベクター製造、遺伝子組み換え、品質管理、規制遵守などが含まれます。このようなサービスの必要性は、特定の遺伝性疾患、がん、その他の症状をターゲットとしたテーラーメイド治療に対する需要を促進する個別化医療とバイオテクノロジーの急速な進歩から生じています。その用途は臨床と商業製造にまたがり、ヘルスケアプロバイダー、製薬会社、研究機関など複数の最終用途産業にサービスを提供しています。市場の成長は、研究開発への投資の増加、技術の進歩、慢性疾患の有病率の上昇といった主要要因の影響を受けています。製造プロセスの自動化とデジタル化、スケーラビリティ・ソリューションの改善、安全性と費用対効果を高める非ウイルス性ベクターの技術革新に大きな機会があります。しかし、市場の成長は、高い開発コスト、複雑な規制状況、細胞・遺伝子治療の輸送・保管をめぐる物流問題などの課題に直面する可能性があります。技術革新の可能性のある分野は、汚染リスクを最小限に抑え、効率を向上させるクローズドシステム製造技術の開発です。製造業者とバイオテクノロジー企業とのパートナーシップの拡大は、採用を加速し、強固なサプライチェーンを促進する可能性があります。こうした力学を理解することは、市場の柔軟でありながら複雑な性質に対する貴重な洞察となります。競合情勢から、企業は進化する技術や規制ガイドラインを常に把握する必要があります。成長機会を活用するために、利害関係者は協調的取り組みを優先し、生産プロセスの最適化に注力し、CRISPRやAI主導型分析などの新技術に投資すべきです。全体として、市場は力強い可能性を示しているが、固有の課題を克服するには戦略的な先見性と機敏性が必要です。

市場力学：急速に進化する細胞・遺伝子治療製造サービス市場の主要市場インサイトを公開

細胞・遺伝子治療製造サービス市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がんおよびその他の対象疾患の高い発生率
  • CDMOによる医薬品研究開発および先端技術への投資の増加
  • 疾病の早期診断に向けた傾向の高まりに伴う個別化医療への注力
• 市場抑制要因
  • 細胞・遺伝子治療製造サービスに関連する高い運用コスト
• 市場機会
  • 細胞・遺伝子治療開発における先端分析技術の登場
  • 細胞・遺伝子治療製造におけるサプライチェーンの改善
• 市場の課題
  • 細胞・遺伝子治療製造における品質管理と汚染の問題

ポーターの5つの力：細胞・遺伝子治療製造サービス市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：細胞・遺伝子治療製造サービス市場における外部からの影響の把握

外部マクロ環境要因は、細胞・遺伝子治療製造サービス市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析細胞・遺伝子治療製造サービス市場における競合情勢の把握

細胞・遺伝子治療製造サービス市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス細胞・遺伝子治療製造サービス市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、細胞・遺伝子治療製造サービス市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんやその他の標的疾患の発生率が高い
    • CDMOによる医薬品研究開発と先端技術への投資増加
    • 早期診断の傾向が高まる中、個別化医療に注目
  • 抑制要因
    • 細胞・遺伝子治療製造サービスに関連する高い運用コスト
  • 機会
    • 細胞・遺伝子治療の開発における先進分析技術の出現
    • 細胞・遺伝子治療製造のサプライチェーンの改善
  • 課題
    • 細胞・遺伝子治療薬製造における品質管理と汚染問題
• 市場セグメンテーション分析
  • タイプ：組織修復および抗炎症治療のための自己間葉系幹細胞の応用
  • 適応症：さまざまな悪性腫瘍の患者に対する個別化医療のための腫瘍治療の潜在的可能性の拡大
  • 応用：初期段階の製品にカスタマイズされた細胞・遺伝子治療製造サービスの大きなメリット
  • エンドユーザー：学術機関や調査機関からの費用対効果の高いサービスに対する高い選好
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 細胞・遺伝子治療製造サービス市場：タイプ別

• 細胞療法
  • 同種異系
    • 同種造血幹細胞
    • 同種人工多能性幹細胞
    • 同種間葉系幹細胞
    • 同種ナチュラルキラー細胞
    • 同種T細胞
  • 自家移植
    • 自己造血幹細胞
    • 自己間葉系幹細胞
    • 自己ナチュラルキラー細胞
    • 自己T細胞
  • ウイルスベクター
    • アデノ随伴ウイルスベクター
    • レトロウイルスベクター
• 遺伝子治療
  • 非ウイルスベクター
  • オリゴヌクレオチド

第7章 細胞・遺伝子治療製造サービス市場適応症別

• 心血管疾患
• 中枢神経系疾患
• 感染症
• 腫瘍疾患
• 眼科疾患
• 整形外科疾患

第8章 細胞・遺伝子治療製造サービス市場：用途別

• 臨床製造
• 商業製造業

第9章 細胞・遺伝子治療製造サービス市場：エンドユーザー別

• 学術調査機関
• 製薬・バイオテクノロジー企業

第10章 南北アメリカの細胞・遺伝子治療製造サービス市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の細胞・遺伝子治療製造サービス市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの細胞・遺伝子治療製造サービス市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 富士フイルム、2億米ドルを投資して事業拡大へ
  • eXmoor Pharma、GMP施設の開設により細胞・遺伝子治療のフルサービスCDMOパートナーに拡大
  • サーモフィッシャーサイエンティフィック、画期的な治療法の開発を加速するためUCSFに細胞治療施設を開設

企業一覧

• uBriGene Biosciences Inc.
• Bluebird Bio, Inc.
• Cell Therapies Pty Ltd.
• Merck KGaA
• Catalent, Inc.
• Miltenyi Biotec B.V. & Co. KG
• Nikon Corporation
• Takara Holdings Inc.
• Charles River Laboratories International, Inc.
• General Electric Company
• Cell and Gene Therapy Catapult
• Boehringer Ingelheim International GmbH
• c-LEcta GmbH
• Advanced BioScience Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Novartis AG
• Cell-Easy SAS
• Samsung Biologics Co., Ltd
• Recipharm AB
• FUJIFILM Diosynth Biotechnologies
• Resonac Corporation
• Exmoor Pharma Concepts Limited
• AGC Biologics
• Bio-Techne Corporation
• Wuxi Apptec Co., Ltd.
• Lonza Group
• Minaris Regenerative Medicine GmbH
• Oxford Biomedica PLC
• F. Hoffmann-La Roche Ltd.

LIST OF FIGURES

• FIGURE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET RESEARCH PROCESS
• FIGURE 2. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL & GENE THERAPY MANUFACTURING SERVICES MARKET DYNAMICS
• TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC T-CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS T-CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY OPHTHALMOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ORTHOPEDIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 75. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 76. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 77. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 78. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. CANADA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 100. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 110. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 112. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 113. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 114. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 115. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 116. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 121. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 122. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 123. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 124. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 125. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 130. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 131. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 132. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 133. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 134. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. INDIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 139. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 140. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 141. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 142. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. INDONESIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 148. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 149. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 150. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 151. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 152. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. JAPAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 157. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 158. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 159. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 160. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 161. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. MALAYSIA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 166. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 167. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 168. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 169. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 170. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. PHILIPPINES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 175. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 176. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 177. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 178. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 179. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. SINGAPORE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 184. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 185. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 186. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 187. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 188. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. SOUTH KOREA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 192. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 193. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 194. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 195. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 196. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 197. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 198. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. TAIWAN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 200. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 202. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 203. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 204. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 205. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 206. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 208. THAILAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 209. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 211. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 212. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 213. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 214. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 215. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 216. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. VIETNAM CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 228. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 230. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 231. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 232. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 233. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 234. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 235. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. DENMARK CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 239. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 240. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 241. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 242. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 243. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 244. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. EGYPT CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 246. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 247. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 248. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 249. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 250. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 251. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 252. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 253. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 254. FINLAND CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 255. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 256. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 257. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 258. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 259. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 260. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 261. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 262. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 263. FRANCE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 264. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 265. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 266. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 267. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 268. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 269. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 270. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 271. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 272. GERMANY CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 274. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 275. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ALLOGENEIC, 2018-2030 (USD MILLION)
• TABLE 276. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY AUTOLOGOUS, 2018-2030 (USD MILLION)
• TABLE 277. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 278. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
• TABLE 279. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 280. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 281. ISRAEL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 282. ITALY CE

The Cell & Gene Therapy Manufacturing Services Market was valued at USD 17.34 billion in 2023, expected to reach USD 19.98 billion in 2024, and is projected to grow at a CAGR of 15.81%, to USD 48.45 billion by 2030.

Cell and gene therapy manufacturing services encompass a wide range of processes involved in producing cell-based and gene-modified therapies. These services include cell culture, viral vector production, genetic modification, quality control, and regulatory compliance. The necessity for such services arises from the rapid advancements in personalized medicine and biotechnology that drive demand for tailored therapies targeting specific genetic diseases, cancers, and other conditions. Their application spans across clinical and commercial manufacturing, serving multiple end-use industries such as healthcare providers, pharmaceutical companies, and research institutions. The market's growth is influenced by key factors such as increasing investments in R&D, technological advancements, and rising prevalence of chronic diseases. Significant opportunities lie in automation and digitalization of manufacturing processes, improved scalability solutions and innovations in non-viral vectors, which can enhance safety and cost-effectiveness. However, market growth can face challenges such as high development costs, complex regulatory landscapes, and logistical issues surrounding the transport and storage of cell and gene therapies. A potential area for innovation is the development of closed-system manufacturing technologies to minimize contamination risk and improve efficiency. Expanding partnerships between manufacturers and biotech companies could accelerate adoption and foster a robust supply chain. Understanding these dynamics provides valuable insight into the market's flexible yet complex nature. The competitive landscape requires companies to stay abreast of evolving technologies and regulatory guidelines. To leverage growth opportunities, stakeholders should prioritize collaborative efforts, focus on optimizing production processes, and invest in new technologies like CRISPR and AI-driven analytics. Overall, while the market shows robust potential, navigating its inherent challenges requires strategic foresight and agility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Manufacturing Services Market

The Cell & Gene Therapy Manufacturing Services Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • High Incidence of Cancer and Other Target Diseases
  • Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
  • Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
• Market Restraints
  • High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
• Market Opportunities
  • Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
  • Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
• Market Challenges
  • Quality Control and Contamination Issues in Cell & Gene Therapy Production

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Manufacturing Services Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Manufacturing Services Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Manufacturing Services Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Manufacturing Services Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Manufacturing Services Market

A detailed market share analysis in the Cell & Gene Therapy Manufacturing Services Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Manufacturing Services Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Manufacturing Services Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include uBriGene Biosciences Inc., Bluebird Bio, Inc., Cell Therapies Pty Ltd., Merck KGaA, Catalent, Inc., Miltenyi Biotec B.V. & Co. KG, Nikon Corporation, Takara Holdings Inc., Charles River Laboratories International, Inc., General Electric Company, Cell and Gene Therapy Catapult, Boehringer Ingelheim International GmbH, c-LEcta GmbH, Advanced BioScience Laboratories, Inc., Thermo Fisher Scientific, Inc., Novartis AG, Cell-Easy SAS, Samsung Biologics Co., Ltd, Recipharm AB, FUJIFILM Diosynth Biotechnologies, Resonac Corporation, Exmoor Pharma Concepts Limited, AGC Biologics, Bio-Techne Corporation, Wuxi Apptec Co., Ltd., Lonza Group, Minaris Regenerative Medicine GmbH, Oxford Biomedica PLC, and F. Hoffmann-La Roche Ltd..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Manufacturing Services Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Cell Therapy and Gene Therapy. The Cell Therapy is further studied across Allogeneic, Autologous, and Viral Vector. The Allogeneic is further studied across Allogeneic Hematopoietic Stem Cells, Allogeneic Induced Pluripotent Stem Cells, Allogeneic Mesenchymal Stem Cells, Allogeneic Natural Killer Cells, and Allogeneic T-cells. The Autologous is further studied across Autologous Hematopoietic Stem Cells, Autologous Mesenchymal Stem Cells, Autologous Natural Killer Cells, and Autologous T-cells. The Viral Vector is further studied across Adeno-associated Virus Vectors and Retroviral Vectors. The Gene Therapy is further studied across Non-viral Vector and Oligonucleotides.
• Based on Indication, market is studied across Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Oncology Diseases, Ophthalmology Diseases, and Orthopedic Diseases.
• Based on Application, market is studied across Clinical Manufacturing and Commercial Manufacturing.
• Based on End-User, market is studied across Academic & Research Institutes and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High Incidence of Cancer and Other Target Diseases
    • 5.1.1.2. Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
    • 5.1.1.3. Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
    • 5.1.3.2. Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Quality Control and Contamination Issues in Cell & Gene Therapy Production
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Applications of autologous mesenchymal stem cells for tissue repair and anti-inflammatory treatments
  • 5.2.2. Indication: Growing potential of oncology therapies for personalized medicine in patients with various malignancies
  • 5.2.3. Application: Significant benefits of customized cell & gene therapy manufacturing services for early-stage products
  • 5.2.4. End-User: Higher preferences for cost-effective services from academic and research institutes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell & Gene Therapy Manufacturing Services Market, by Type

• 6.1. Introduction
• 6.2. Cell Therapy
  • 6.2.1. Allogeneic
    • 6.2.1.1. Allogeneic Hematopoietic Stem Cells
    • 6.2.1.2. Allogeneic Induced Pluripotent Stem Cells
    • 6.2.1.3. Allogeneic Mesenchymal Stem Cells
    • 6.2.1.4. Allogeneic Natural Killer Cells
    • 6.2.1.5. Allogeneic T-cells
  • 6.2.2. Autologous
    • 6.2.2.1. Autologous Hematopoietic Stem Cells
    • 6.2.2.2. Autologous Mesenchymal Stem Cells
    • 6.2.2.3. Autologous Natural Killer Cells
    • 6.2.2.4. Autologous T-cells
  • 6.2.3. Viral Vector
    • 6.2.3.1. Adeno-associated Virus Vectors
    • 6.2.3.2. Retroviral Vectors
• 6.3. Gene Therapy
  • 6.3.1. Non-viral Vector
  • 6.3.2. Oligonucleotides

7. Cell & Gene Therapy Manufacturing Services Market, by Indication

• 7.1. Introduction
• 7.2. Cardiovascular Diseases
• 7.3. Central Nervous System Disorders
• 7.4. Infectious Diseases
• 7.5. Oncology Diseases
• 7.6. Ophthalmology Diseases
• 7.7. Orthopedic Diseases

8. Cell & Gene Therapy Manufacturing Services Market, by Application

• 8.1. Introduction
• 8.2. Clinical Manufacturing
• 8.3. Commercial Manufacturing

9. Cell & Gene Therapy Manufacturing Services Market, by End-User

• 9.1. Introduction
• 9.2. Academic & Research Institutes
• 9.3. Pharmaceutical & Biotechnology Companies

10. Americas Cell & Gene Therapy Manufacturing Services Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Fujifilm to Invest USD 200 Million to Expand
  • 13.3.2. eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
  • 13.3.3. Thermo Fisher Scientific Opens Cell Therapy Facility at UCSF to Accelerate Development of Breakthrough Therapies

Companies Mentioned

• 1. uBriGene Biosciences Inc.
• 2. Bluebird Bio, Inc.
• 3. Cell Therapies Pty Ltd.
• 4. Merck KGaA
• 5. Catalent, Inc.
• 6. Miltenyi Biotec B.V. & Co. KG
• 7. Nikon Corporation
• 8. Takara Holdings Inc.
• 9. Charles River Laboratories International, Inc.
• 10. General Electric Company
• 11. Cell and Gene Therapy Catapult
• 12. Boehringer Ingelheim International GmbH
• 13. c-LEcta GmbH
• 14. Advanced BioScience Laboratories, Inc.
• 15. Thermo Fisher Scientific, Inc.
• 16. Novartis AG
• 17. Cell-Easy SAS
• 18. Samsung Biologics Co., Ltd
• 19. Recipharm AB
• 20. FUJIFILM Diosynth Biotechnologies
• 21. Resonac Corporation
• 22. Exmoor Pharma Concepts Limited
• 23. AGC Biologics
• 24. Bio-Techne Corporation
• 25. Wuxi Apptec Co., Ltd.
• 26. Lonza Group
• 27. Minaris Regenerative Medicine GmbH
• 28. Oxford Biomedica PLC
• 29. F. Hoffmann-La Roche Ltd.